Regulus Therapeutics Inc (RGLS) Given Consensus Recommendation of “Hold” by Analysts

Regulus Therapeutics Inc (NASDAQ:RGLS) has been assigned a consensus recommendation of “Hold” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a hold rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $1.13.

Several equities research analysts have recently issued reports on RGLS shares. Wedbush reissued a “hold” rating and issued a $1.00 price objective on shares of Regulus Therapeutics in a research report on Friday, August 10th. Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a research report on Friday, August 10th. Finally, Zacks Investment Research lowered shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th.

Shares of Regulus Therapeutics stock traded down $0.04 during trading hours on Monday, hitting $1.61. The company’s stock had a trading volume of 90,266 shares, compared to its average volume of 355,925. Regulus Therapeutics has a 1-year low of $1.04 and a 1-year high of $17.28. The firm has a market capitalization of $14.44 million, a P/E ratio of -0.14 and a beta of 1.78.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.25) by $0.07. Regulus Therapeutics had a negative net margin of 75,823.62% and a negative return on equity of 311.60%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Sell-side analysts forecast that Regulus Therapeutics will post -4.58 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Regulus Therapeutics stock. Renaissance Technologies LLC increased its position in Regulus Therapeutics Inc (NASDAQ:RGLS) by 396.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 595,501 shares of the biopharmaceutical company’s stock after purchasing an additional 475,512 shares during the quarter. Renaissance Technologies LLC owned 6.82% of Regulus Therapeutics worth $118,000 as of its most recent filing with the Securities and Exchange Commission.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Featured Story: What is an SEC Filing?

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit